Recent news on Human Secretin

Repligen Reports Positive Phase 2 Clinical Trial Results Of ...  -  May 11, 2007
Medical News Today (press release),Repligen Corporation (Nasdaq: RGEN) announced today positive results from a Phase 2 clinical trial to evaluate the use of RG1068, synthetic human secretin,

Repligen "market outperform," target price raised  -  Apr 12, 2007
newratings.comFreidreich’s Ataxia (FA), the analysts say. The company is progressing with its study of human secretin for pancreatic imaging, Rodman & Renshaw adds.

Repligen Reports Third Quarter Fiscal Year 2007 Financial Results  -  Feb 8, 2007
Earthtimes.orgSecretin * This quarter we completed enrollment in a clinical trial to evaluate the use of RG1068, synthetic human secretin, to aid in the detection of

Repligen Reports Second Quarter Fiscal Year 2007 Financial Results  Nov 2, 2006
Earlier this week we reported the initiation of a clinical study to evaluate the diagnostic utility of RG1068, synthetic human secretin, in functional magnetic ... -Yahoo! News (press release) Repligen tests non-invasive pancreas drug  Oct 30, 2006
...said Monday it has started a clinical study to evaluate the usefulness of RG1068, synthetic human secretin, in non-invasive tests to detect early stage ... -Boston Business Journal, Market Report -- In Play (RGEN)  Oct 30, 2006
...of the Pancreas Co announces the initiation of a clinical study to evaluate the diagnostic utility of RG1068, synthetic human secretin, in functional magnetic ... -MSN Money Repligen Reports Initiation Of A Clinical Study Of Secretin For ...  Oct 31, 2006
Nasdaq: RGEN) today reported the initiation of a clinical study to evaluate the diagnostic utility of RG1068, synthetic human secretin, in functional magnetic ... -Medical News Today (press release), ChiRhoClin Announces a Human Secretin Study Completed for MRCP Imaging  -  12 Dec 2006
Business Wire (press release),This study utilized human secretin enhanced MRCP (sMRCP) as a pancreas function test and compared the results to the current “Gold Standard� secretin

Repligen drug granted orphan status  -  12 Dec 2006
Boston Business Journal,RG1068 is synthetic human secretin, a version of a natural gastrointestinal hormone involved in digestion. The hormone has been used in the past,

Orphan Drug Status Granted for Synthetic Human Secretin (RG1068)  -  Nov 21, 2006
Facts and Comparisons,The FDA has granted orphan drug status to Repligen Corporation’s RG1068 (synthetic human secretin) for use with magnetic resonance imaging (MRI) of the

ChiRhoClin Announces a Human Secretin Study Completed for MRCP Imaging  -  Nov 13, 2006
Genetic Engineering News (press release),One of ChiRhoClin's independent investigators has completed a human secretin enhanced MRCP study and recently reported the results at 2006 Joint Meeting of

Repligen MRI product gets orphan status  -  Nov 21, 2006
ReutersO: Quote, Profile, Research) said on Tuesday its synthetic human secretin for use with magnetic resonance imaging of the pancreas had received orphan drug

Repligen Receives Orphan Drug Designation From The FDA For RG1068 ...  -  Nov 22, 2006
Medical News Today (press release),Administration (FDA) granted orphan drug designation to RG1068, synthetic human secretin, for use with magnetic resonance imaging (MRI) of the pancreas.



Repligen Reports Third Quarter 2006 Financial Results  09 Feb 2006
We are currently in discussions with the FDA on the criteria for approval to market our synthetic human secretin product (RG1068) for improvement of MRI ... - Finanzen.net

Secretin should not be used to treat autism, researchers say  Jan 27, 2006
The patients, ranging in age from 3 to 15 years old, were given either synthetic human secretin or pig secretin or a saline placebo intravenously. ... - SheKnows.com

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional